Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 54 | 2020 | 488 | 7.500 |
Why?
|
Substance-Related Disorders | 26 | 2019 | 97 | 7.080 |
Why?
|
HIV Seropositivity | 24 | 2019 | 51 | 3.930 |
Why?
|
Neuropsychological Tests | 66 | 2019 | 1226 | 3.540 |
Why?
|
AIDS Dementia Complex | 15 | 2018 | 40 | 2.080 |
Why?
|
Cognition Disorders | 18 | 2018 | 1003 | 1.890 |
Why?
|
Psychomotor Performance | 18 | 2018 | 212 | 1.750 |
Why?
|
Memory Disorders | 9 | 2017 | 162 | 1.710 |
Why?
|
Decision Making | 9 | 2016 | 226 | 1.580 |
Why?
|
Adult | 88 | 2019 | 8097 | 1.580 |
Why?
|
Cognition | 22 | 2019 | 1352 | 1.500 |
Why?
|
Sex Characteristics | 5 | 2018 | 118 | 1.420 |
Why?
|
Middle Aged | 77 | 2020 | 9250 | 1.420 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2017 | 45 | 1.390 |
Why?
|
Memory, Short-Term | 12 | 2019 | 100 | 1.330 |
Why?
|
Hepatitis C | 5 | 2015 | 46 | 1.280 |
Why?
|
Male | 86 | 2020 | 15269 | 1.220 |
Why?
|
Impulsive Behavior | 6 | 2013 | 15 | 1.200 |
Why?
|
Humans | 110 | 2020 | 28395 | 1.060 |
Why?
|
Anti-HIV Agents | 10 | 2019 | 71 | 1.050 |
Why?
|
Reaction Time | 15 | 2018 | 106 | 1.040 |
Why?
|
Learning | 3 | 2013 | 73 | 1.030 |
Why?
|
Attention | 11 | 2019 | 131 | 0.990 |
Why?
|
Drug Users | 3 | 2015 | 3 | 0.960 |
Why?
|
Female | 64 | 2019 | 15704 | 0.950 |
Why?
|
HIV-1 | 15 | 2017 | 236 | 0.940 |
Why?
|
Risk-Taking | 4 | 2016 | 35 | 0.910 |
Why?
|
Cocaine-Related Disorders | 4 | 2017 | 13 | 0.890 |
Why?
|
Cognitive Dysfunction | 9 | 2020 | 1065 | 0.880 |
Why?
|
Antiretroviral Therapy, Highly Active | 10 | 2017 | 62 | 0.870 |
Why?
|
Neurocognitive Disorders | 3 | 2019 | 13 | 0.830 |
Why?
|
Gambling | 6 | 2013 | 8 | 0.720 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 13 | 0.670 |
Why?
|
Memory, Episodic | 2 | 2017 | 116 | 0.650 |
Why?
|
HIV Seronegativity | 6 | 2016 | 17 | 0.580 |
Why?
|
Spatial Learning | 1 | 2017 | 4 | 0.580 |
Why?
|
Spatial Navigation | 1 | 2017 | 3 | 0.580 |
Why?
|
Mumps | 1 | 2017 | 1 | 0.570 |
Why?
|
Mumps Vaccine | 1 | 2017 | 1 | 0.570 |
Why?
|
Immunization Programs | 1 | 2017 | 2 | 0.570 |
Why?
|
Epidemiological Monitoring | 1 | 2017 | 8 | 0.570 |
Why?
|
Homosexuality, Male | 5 | 2017 | 27 | 0.550 |
Why?
|
Mental Recall | 3 | 2016 | 63 | 0.530 |
Why?
|
Executive Function | 9 | 2019 | 115 | 0.530 |
Why?
|
Memory | 7 | 2019 | 302 | 0.520 |
Why?
|
Marijuana Abuse | 3 | 2014 | 6 | 0.510 |
Why?
|
Depression | 7 | 2019 | 452 | 0.490 |
Why?
|
Delay Discounting | 1 | 2015 | 24 | 0.480 |
Why?
|
Brain | 10 | 2020 | 1663 | 0.480 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2015 | 235 | 0.470 |
Why?
|
Hospitalization | 1 | 2017 | 323 | 0.470 |
Why?
|
Verbal Learning | 6 | 2015 | 34 | 0.460 |
Why?
|
Heroin Dependence | 5 | 2013 | 9 | 0.450 |
Why?
|
Schizophrenic Psychology | 4 | 2002 | 14 | 0.450 |
Why?
|
Cohort Studies | 18 | 2020 | 1926 | 0.440 |
Why?
|
Antisocial Personality Disorder | 3 | 2010 | 8 | 0.440 |
Why?
|
Sex Factors | 6 | 2019 | 475 | 0.430 |
Why?
|
Adolescent | 12 | 2017 | 2307 | 0.410 |
Why?
|
Severity of Illness Index | 6 | 2019 | 985 | 0.400 |
Why?
|
Suicide, Attempted | 1 | 2012 | 16 | 0.390 |
Why?
|
Amphetamine-Related Disorders | 2 | 2013 | 5 | 0.390 |
Why?
|
Young Adult | 10 | 2019 | 2069 | 0.380 |
Why?
|
Analysis of Variance | 6 | 2011 | 269 | 0.380 |
Why?
|
Serial Learning | 1 | 2011 | 7 | 0.370 |
Why?
|
Unsafe Sex | 1 | 2010 | 2 | 0.350 |
Why?
|
Affective Symptoms | 1 | 2010 | 12 | 0.350 |
Why?
|
Motor Skills | 1 | 2010 | 52 | 0.340 |
Why?
|
Age Factors | 9 | 2019 | 781 | 0.340 |
Why?
|
Case-Control Studies | 9 | 2019 | 593 | 0.330 |
Why?
|
Central Nervous System Diseases | 1 | 2009 | 18 | 0.320 |
Why?
|
Alcoholism | 3 | 2014 | 74 | 0.310 |
Why?
|
Women | 1 | 2008 | 14 | 0.310 |
Why?
|
Neuropsychology | 1 | 2008 | 11 | 0.300 |
Why?
|
Auditory Perception | 3 | 2006 | 43 | 0.300 |
Why?
|
Career Choice | 1 | 2008 | 30 | 0.300 |
Why?
|
Professional Role | 1 | 2008 | 36 | 0.300 |
Why?
|
Diabetes Complications | 2 | 2018 | 59 | 0.300 |
Why?
|
Marijuana Smoking | 2 | 2019 | 3 | 0.300 |
Why?
|
Choice Behavior | 4 | 2013 | 46 | 0.290 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 492 | 0.290 |
Why?
|
Comorbidity | 4 | 2015 | 500 | 0.280 |
Why?
|
Substance Abuse, Intravenous | 2 | 2005 | 10 | 0.280 |
Why?
|
Practice Patterns, Physicians' | 1 | 2008 | 122 | 0.280 |
Why?
|
Schizophrenia | 3 | 2002 | 63 | 0.280 |
Why?
|
Prefrontal Cortex | 4 | 2014 | 137 | 0.280 |
Why?
|
Methamphetamine | 1 | 2007 | 23 | 0.270 |
Why?
|
Magnetic Resonance Imaging | 9 | 2020 | 1143 | 0.260 |
Why?
|
Aged | 17 | 2019 | 9256 | 0.250 |
Why?
|
Depressive Disorder | 3 | 2014 | 185 | 0.250 |
Why?
|
Risk Factors | 12 | 2018 | 2408 | 0.240 |
Why?
|
Exploratory Behavior | 1 | 2005 | 10 | 0.240 |
Why?
|
Statistics as Topic | 3 | 2013 | 107 | 0.240 |
Why?
|
Psychometrics | 4 | 2013 | 244 | 0.240 |
Why?
|
Cross-Sectional Studies | 5 | 2019 | 932 | 0.240 |
Why?
|
Problem Solving | 2 | 2002 | 47 | 0.240 |
Why?
|
Sexual Behavior | 1 | 2005 | 57 | 0.230 |
Why?
|
Psychiatric Status Rating Scales | 8 | 2008 | 324 | 0.230 |
Why?
|
Stress, Psychological | 2 | 2017 | 241 | 0.220 |
Why?
|
Longitudinal Studies | 9 | 2018 | 1384 | 0.220 |
Why?
|
Visual Perception | 2 | 2016 | 30 | 0.210 |
Why?
|
Individuality | 2 | 2018 | 24 | 0.210 |
Why?
|
Concept Formation | 1 | 2002 | 9 | 0.210 |
Why?
|
Social Adjustment | 1 | 2002 | 26 | 0.200 |
Why?
|
Prospective Studies | 11 | 2018 | 1804 | 0.200 |
Why?
|
Psychotic Disorders | 1 | 2002 | 46 | 0.200 |
Why?
|
Personality | 2 | 2013 | 54 | 0.190 |
Why?
|
Self Report | 3 | 2018 | 221 | 0.190 |
Why?
|
Intelligence Tests | 2 | 2011 | 15 | 0.180 |
Why?
|
Cues | 2 | 2000 | 43 | 0.180 |
Why?
|
Educational Status | 5 | 2015 | 298 | 0.180 |
Why?
|
Central Nervous System Stimulants | 3 | 2017 | 41 | 0.170 |
Why?
|
Bipolar Disorder | 2 | 2002 | 132 | 0.170 |
Why?
|
Thinking | 1 | 2000 | 17 | 0.170 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 128 | 0.170 |
Why?
|
White Matter | 2 | 2018 | 134 | 0.170 |
Why?
|
Benzoxazines | 1 | 2019 | 3 | 0.160 |
Why?
|
Drug Substitution | 1 | 2019 | 4 | 0.160 |
Why?
|
Obesity, Abdominal | 1 | 2019 | 19 | 0.160 |
Why?
|
Demography | 3 | 2014 | 73 | 0.150 |
Why?
|
Disease Progression | 3 | 2015 | 717 | 0.150 |
Why?
|
Energy Metabolism | 1 | 2018 | 55 | 0.150 |
Why?
|
Incidence | 2 | 2018 | 773 | 0.150 |
Why?
|
Vaccination Coverage | 1 | 2017 | 1 | 0.140 |
Why?
|
Spain | 1 | 2017 | 9 | 0.140 |
Why?
|
Chicago | 3 | 2013 | 939 | 0.140 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2010 | 42 | 0.140 |
Why?
|
Crack Cocaine | 2 | 2014 | 2 | 0.140 |
Why?
|
Marijuana Use | 1 | 2017 | 1 | 0.140 |
Why?
|
Vaccination | 1 | 2017 | 31 | 0.140 |
Why?
|
Psychological Tests | 3 | 2007 | 53 | 0.140 |
Why?
|
Host-Pathogen Interactions | 1 | 2017 | 14 | 0.140 |
Why?
|
United States | 8 | 2019 | 2196 | 0.140 |
Why?
|
Disease Outbreaks | 1 | 2017 | 82 | 0.140 |
Why?
|
Personality Tests | 1 | 2016 | 5 | 0.140 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 56 | 0.140 |
Why?
|
Sexual and Gender Minorities | 1 | 2017 | 25 | 0.130 |
Why?
|
Aged, 80 and over | 8 | 2019 | 4851 | 0.130 |
Why?
|
Antirheumatic Agents | 1 | 2017 | 86 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2014 | 284 | 0.130 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 138 | 0.130 |
Why?
|
Aging | 3 | 2017 | 1549 | 0.130 |
Why?
|
Obesity | 2 | 2019 | 321 | 0.130 |
Why?
|
Time Factors | 4 | 2013 | 1490 | 0.130 |
Why?
|
Cerebral Cortex | 2 | 2016 | 161 | 0.130 |
Why?
|
Personality Inventory | 1 | 2016 | 73 | 0.130 |
Why?
|
Smoking | 1 | 2017 | 176 | 0.130 |
Why?
|
Infant | 1 | 2017 | 587 | 0.120 |
Why?
|
Adiponectin | 1 | 2015 | 10 | 0.120 |
Why?
|
Hippocampus | 1 | 2017 | 278 | 0.120 |
Why?
|
RNA, Viral | 1 | 2015 | 45 | 0.120 |
Why?
|
Child, Preschool | 1 | 2017 | 689 | 0.120 |
Why?
|
Chi-Square Distribution | 3 | 2014 | 146 | 0.120 |
Why?
|
Catechol O-Methyltransferase | 1 | 2014 | 2 | 0.120 |
Why?
|
Interleukin-6 | 1 | 2015 | 79 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 4 | 2017 | 54 | 0.120 |
Why?
|
Prevalence | 4 | 2017 | 467 | 0.110 |
Why?
|
Gyrus Cinguli | 1 | 2014 | 14 | 0.110 |
Why?
|
Drug Therapy, Combination | 3 | 2017 | 183 | 0.110 |
Why?
|
Quality of Life | 1 | 2019 | 658 | 0.110 |
Why?
|
Menopause | 1 | 2014 | 99 | 0.110 |
Why?
|
Zidovudine | 3 | 1999 | 13 | 0.110 |
Why?
|
Genotype | 4 | 2014 | 359 | 0.100 |
Why?
|
Child | 1 | 2017 | 1421 | 0.100 |
Why?
|
Patient Selection | 1 | 2014 | 206 | 0.100 |
Why?
|
Anxiety | 2 | 2010 | 161 | 0.100 |
Why?
|
Apolipoprotein E4 | 1 | 2014 | 264 | 0.100 |
Why?
|
Viral Load | 3 | 2017 | 73 | 0.100 |
Why?
|
Association Learning | 1 | 2012 | 2 | 0.100 |
Why?
|
Hospitals, Veterans | 1 | 2012 | 6 | 0.100 |
Why?
|
Follow-Up Studies | 6 | 2015 | 1858 | 0.100 |
Why?
|
Regression Analysis | 4 | 2016 | 266 | 0.100 |
Why?
|
Orientation | 1 | 1992 | 5 | 0.100 |
Why?
|
Pattern Recognition, Visual | 1 | 1992 | 18 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 97 | 0.100 |
Why?
|
Socioeconomic Factors | 2 | 2010 | 308 | 0.100 |
Why?
|
Blood Platelets | 1 | 2011 | 39 | 0.090 |
Why?
|
Caudate Nucleus | 1 | 2011 | 11 | 0.090 |
Why?
|
Reading | 1 | 2011 | 37 | 0.090 |
Why?
|
Bethanechol Compounds | 2 | 1988 | 5 | 0.090 |
Why?
|
Putamen | 1 | 2011 | 20 | 0.090 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 283 | 0.090 |
Why?
|
Surveys and Questionnaires | 4 | 2019 | 1215 | 0.090 |
Why?
|
Psychomotor Disorders | 1 | 2010 | 11 | 0.090 |
Why?
|
Stroop Test | 1 | 2010 | 3 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 116 | 0.090 |
Why?
|
Stroke | 1 | 2013 | 274 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2010 | 83 | 0.090 |
Why?
|
Games, Experimental | 1 | 2009 | 7 | 0.080 |
Why?
|
Atrophy | 3 | 2016 | 93 | 0.080 |
Why?
|
Social Values | 1 | 2008 | 10 | 0.080 |
Why?
|
Frontal Lobe | 2 | 1995 | 81 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2015 | 331 | 0.080 |
Why?
|
Antipsychotic Agents | 2 | 2002 | 65 | 0.080 |
Why?
|
Dementia | 1 | 2014 | 573 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 5 | 1996 | 80 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2012 | 733 | 0.080 |
Why?
|
Gray Matter | 2 | 2020 | 51 | 0.070 |
Why?
|
HIV | 2 | 2011 | 43 | 0.070 |
Why?
|
Infusion Pumps | 1 | 1988 | 6 | 0.070 |
Why?
|
Alzheimer Disease | 4 | 1992 | 2118 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2008 | 137 | 0.070 |
Why?
|
Leadership | 1 | 2008 | 107 | 0.070 |
Why?
|
Societies, Medical | 1 | 2008 | 154 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2007 | 95 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2017 | 3609 | 0.070 |
Why?
|
Bisexuality | 2 | 2017 | 7 | 0.070 |
Why?
|
Mental Health | 2 | 2019 | 122 | 0.060 |
Why?
|
Depressive Disorder, Major | 2 | 2003 | 102 | 0.060 |
Why?
|
Research | 1 | 2005 | 43 | 0.060 |
Why?
|
Intracranial Arteriovenous Malformations | 2 | 1995 | 10 | 0.060 |
Why?
|
Homosexuality | 2 | 2015 | 6 | 0.060 |
Why?
|
Substance Abuse Detection | 1 | 2004 | 5 | 0.060 |
Why?
|
Activities of Daily Living | 3 | 2002 | 608 | 0.060 |
Why?
|
Alleles | 2 | 2014 | 221 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2004 | 80 | 0.060 |
Why?
|
Organ Size | 2 | 2016 | 100 | 0.060 |
Why?
|
Gene Expression | 2 | 2014 | 202 | 0.060 |
Why?
|
Probability | 1 | 2004 | 90 | 0.060 |
Why?
|
Electroconvulsive Therapy | 1 | 2003 | 16 | 0.050 |
Why?
|
Electric Stimulation | 1 | 2003 | 53 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2013 | 25 | 0.050 |
Why?
|
Schizotypal Personality Disorder | 1 | 1982 | 2 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2002 | 32 | 0.050 |
Why?
|
Rehabilitation, Vocational | 1 | 2002 | 2 | 0.050 |
Why?
|
Delusions | 1 | 2002 | 10 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2002 | 94 | 0.050 |
Why?
|
Hallucinations | 1 | 2002 | 64 | 0.050 |
Why?
|
Communication | 1 | 1982 | 124 | 0.050 |
Why?
|
Reference Values | 4 | 2012 | 194 | 0.050 |
Why?
|
Patient Discharge | 1 | 2002 | 163 | 0.050 |
Why?
|
Chronic Disease | 1 | 2002 | 441 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 372 | 0.040 |
Why?
|
Zalcitabine | 1 | 1999 | 1 | 0.040 |
Why?
|
Didanosine | 1 | 1999 | 3 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 1999 | 4 | 0.040 |
Why?
|
Alkynes | 1 | 2019 | 4 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2019 | 15 | 0.040 |
Why?
|
Waist Circumference | 1 | 2019 | 35 | 0.040 |
Why?
|
Cities | 1 | 2018 | 17 | 0.040 |
Why?
|
Movement | 1 | 2019 | 117 | 0.040 |
Why?
|
Posture | 1 | 1998 | 66 | 0.040 |
Why?
|
Parietal Lobe | 2 | 1995 | 17 | 0.040 |
Why?
|
Postoperative Complications | 2 | 1995 | 931 | 0.040 |
Why?
|
Dominance, Cerebral | 2 | 1995 | 16 | 0.040 |
Why?
|
Pilot Projects | 1 | 1999 | 439 | 0.040 |
Why?
|
Cell Count | 1 | 2017 | 79 | 0.040 |
Why?
|
CD4 Antigens | 1 | 2017 | 29 | 0.040 |
Why?
|
Radiography | 2 | 2011 | 639 | 0.040 |
Why?
|
Tobacco Smoking | 1 | 2017 | 5 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2017 | 46 | 0.040 |
Why?
|
Systems Biology | 1 | 2017 | 6 | 0.030 |
Why?
|
Mental Status and Dementia Tests | 1 | 2017 | 69 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 29 | 0.030 |
Why?
|
Dopamine | 2 | 2014 | 87 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 465 | 0.030 |
Why?
|
Medication Adherence | 1 | 2017 | 81 | 0.030 |
Why?
|
Cerebrovascular Circulation | 2 | 1995 | 34 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 27 | 0.030 |
Why?
|
Language | 1 | 1996 | 71 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2017 | 539 | 0.030 |
Why?
|
Language Disorders | 1 | 1995 | 7 | 0.030 |
Why?
|
Leptin | 1 | 2015 | 22 | 0.030 |
Why?
|
Serotyping | 1 | 2014 | 10 | 0.030 |
Why?
|
Methylphenidate | 1 | 1995 | 8 | 0.030 |
Why?
|
Hematoma | 1 | 1995 | 19 | 0.030 |
Why?
|
Anomia | 1 | 1994 | 1 | 0.030 |
Why?
|
Aphasia, Broca | 1 | 1994 | 2 | 0.030 |
Why?
|
Temporal Lobe | 1 | 1995 | 84 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2015 | 104 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 129 | 0.030 |
Why?
|
Smoking Prevention | 2 | 1986 | 17 | 0.030 |
Why?
|
Chemokine CCL3 | 1 | 2014 | 9 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2015 | 78 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2014 | 19 | 0.030 |
Why?
|
Survival Analysis | 1 | 2014 | 267 | 0.030 |
Why?
|
Motivation | 1 | 1995 | 99 | 0.030 |
Why?
|
Models, Neurological | 1 | 1994 | 25 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 1995 | 148 | 0.030 |
Why?
|
Heroin | 1 | 2013 | 2 | 0.030 |
Why?
|
Avoidance Learning | 2 | 2010 | 6 | 0.030 |
Why?
|
Color Perception | 1 | 1992 | 5 | 0.030 |
Why?
|
Cannabis | 1 | 2012 | 10 | 0.030 |
Why?
|
Quality Control | 1 | 2012 | 32 | 0.020 |
Why?
|
Models, Genetic | 1 | 2012 | 42 | 0.020 |
Why?
|
Haplotypes | 1 | 2012 | 59 | 0.020 |
Why?
|
Biomarkers | 1 | 2015 | 596 | 0.020 |
Why?
|
Platelet Count | 1 | 2011 | 16 | 0.020 |
Why?
|
Animals | 2 | 2018 | 3780 | 0.020 |
Why?
|
Bethanechol | 2 | 1988 | 4 | 0.020 |
Why?
|
Health Surveys | 1 | 2011 | 88 | 0.020 |
Why?
|
Phenotype | 1 | 2012 | 310 | 0.020 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2010 | 5 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2011 | 67 | 0.020 |
Why?
|
Neuroimaging | 1 | 2011 | 128 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 51 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2010 | 48 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 352 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 169 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 390 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2011 | 199 | 0.020 |
Why?
|
Verbal Behavior | 2 | 1994 | 16 | 0.020 |
Why?
|
Ultrasonography | 1 | 2011 | 243 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 825 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 377 | 0.020 |
Why?
|
Behavior | 1 | 1988 | 25 | 0.020 |
Why?
|
Anisotropy | 1 | 2008 | 47 | 0.020 |
Why?
|
Mental Status Schedule | 1 | 1988 | 93 | 0.020 |
Why?
|
Affect | 1 | 2008 | 59 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1988 | 351 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2007 | 94 | 0.020 |
Why?
|
Mental Processes | 1 | 2006 | 19 | 0.020 |
Why?
|
Reference Standards | 1 | 2006 | 25 | 0.020 |
Why?
|
Biopsy | 1 | 1987 | 220 | 0.020 |
Why?
|
Counseling | 1 | 1986 | 45 | 0.020 |
Why?
|
Intelligence | 1 | 2005 | 19 | 0.020 |
Why?
|
Regional Blood Flow | 2 | 1995 | 8 | 0.010 |
Why?
|
Behavior Therapy | 1 | 1986 | 91 | 0.010 |
Why?
|
Parkinson Disease | 1 | 1992 | 844 | 0.010 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2003 | 17 | 0.010 |
Why?
|
Aversive Therapy | 1 | 1983 | 1 | 0.010 |
Why?
|
Hypophysectomy | 1 | 1983 | 3 | 0.010 |
Why?
|
Schizophrenic Language | 1 | 1982 | 1 | 0.010 |
Why?
|
Morphine | 1 | 1983 | 61 | 0.010 |
Why?
|
Motor Activity | 1 | 2003 | 329 | 0.010 |
Why?
|
Reflex | 1 | 1998 | 2 | 0.010 |
Why?
|
Electromyography | 1 | 1998 | 71 | 0.010 |
Why?
|
Leg | 1 | 1998 | 52 | 0.010 |
Why?
|
Forecasting | 1 | 1998 | 103 | 0.010 |
Why?
|
Rotation | 1 | 1998 | 137 | 0.010 |
Why?
|
Epilepsy | 1 | 1996 | 64 | 0.010 |
Why?
|
Bolivia | 1 | 1995 | 3 | 0.010 |
Why?
|
Amobarbital | 1 | 1995 | 2 | 0.010 |
Why?
|
Epilepsy, Generalized | 1 | 1995 | 2 | 0.010 |
Why?
|
Arteriovenous Malformations | 1 | 1995 | 3 | 0.010 |
Why?
|
Social Behavior | 1 | 1995 | 67 | 0.010 |
Why?
|
Dopamine D2 Receptor Antagonists | 1 | 1994 | 1 | 0.010 |
Why?
|
Receptors, Dopamine D2 | 1 | 1994 | 12 | 0.010 |
Why?
|
Neural Pathways | 1 | 1994 | 65 | 0.010 |
Why?
|
Postoperative Period | 1 | 1995 | 331 | 0.010 |
Why?
|
Cerebral Ventricles | 1 | 1988 | 19 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1988 | 432 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1988 | 239 | 0.000 |
Why?
|
Treatment Outcome | 1 | 1995 | 3615 | 0.000 |
Why?
|
Conditioning, Classical | 1 | 1983 | 4 | 0.000 |
Why?
|
Drug Tolerance | 1 | 1983 | 7 | 0.000 |
Why?
|
Rats | 1 | 1983 | 678 | 0.000 |
Why?
|